

Supplementary Table 2. Cabozantinib combination details (*n* = 15)

<i>n</i> (%)		
Any ICI		15 (100%)
ICI used	Anti-PD-1 only	4 (26.7%)
	Anti-PD-1 + Anti-CTLA-4	11 (73.3%)
Others		2 (13.3%)